EKF Diagnostics enters collaborative relationship with Joslin Diabetes Center
EKF Diagnostics has entered a multi-year, collaborative relationship with Joslin Diabetes Center (“Joslin”) in support of the ongoing clinical and commercial translation of TNFR1 & 2 biomarkers. These novel biomarkers can help identify patients with Type 1 and Type 2 diabetes that are at an increased risk of developing end stage renal disease (ESRD), up to ten years in advance. The new agreement between Joslin, an affiliate of Harvard Medical School, and EKF is part of Joslin’s Corporate Liaison Program (CLP). This programme seeks to accelerate development, validation and market introduction of unique products and solutions that advance treatments and care for diabetes and its complications. As globally recognized leaders in the field of diabetes research, Joslin has created the CLP in order to foster industry partnerships within the pharmaceutical, biotechnology, food and device industries. The role of the CLP is to help engage corporate partners, such as EKF, with Joslin’s capabilities in advisory services, clinical expertise, and research infrastructure. This enables Joslin to work closely with an industry partner to customize its offerings towards a defined product programme or a range of corporate priorities within diabetes management. EKF will access certain clinical and research expertise at Joslin under the CLP to further develop its TNFR biomarker test. The two key objectives of this effort are to (a) accelerate the clinical development, as well as understanding physician adoption criteria and trends relating to the TNFR-1/2 test; (b) advance the research to support the clinical utility of TNFR 1&2 assays as biomarkers in diabetic kidney disease. This will be accomplished in part by leveraging the collaboration of Joslin with certain partners in the pharmaceutical industry.
www.ekfdiagnostics.com
